Blue Trust Inc. grew its stake in McKesson Corporation (NYSE:MCK – Free Report) by 13.8% during the first quarter, Holdings Channel.com reports. The fund owned 5,932 shares of the company’s stock after purchasing an additional 719 shares during the quarter. Blue Trust Inc.’s holdings in McKesson were worth $5,133,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. GGM Financials LLC bought a new stake in shares of McKesson during the third quarter valued at approximately $25,000. University of Texas Texas AM Investment Management Co. bought a new position in McKesson in the fourth quarter worth approximately $25,000. Swiss RE Ltd. purchased a new position in McKesson during the 4th quarter worth $26,000. State of Wyoming purchased a new position in McKesson during the 2nd quarter worth $29,000. Finally, Vermillion & White Wealth Management Group LLC purchased a new position in McKesson during the 3rd quarter worth $33,000. 85.07% of the stock is owned by hedge funds and other institutional investors.
Key Headlines Impacting McKesson
Here are the key news stories impacting McKesson this week:
- Positive Sentiment: McKesson announced a $179 million, state-of-the-art pharmaceutical distribution center in Moore, Oklahoma, a sign of continued investment in its healthcare logistics network and capacity expansion. McKesson Selects Moore, Oklahoma for $179 Million State-of-the-Art Pharmaceutical Distribution Center
- Positive Sentiment: Related reports say the new Moore facility will be a 330,000-square-foot distribution hub and could create 200+ jobs, reinforcing McKesson’s role as a key healthcare supply-chain operator. McKesson picks Moore for 330,000-square-foot distribution hub, 200+ jobs expected
- Positive Sentiment: McKesson also announced its first-quarter fiscal 2027 earnings release date for August 5, which gives investors a clear near-term catalyst to watch. McKesson Corporation Announces First Quarter Fiscal 2027 Earnings Release Date
- Positive Sentiment: The company’s annual ideaShare 2026 event highlighted momentum with independent pharmacies, which may support customer relationships and future distribution demand. McKesson ideaShare 2026 Fuels Momentum for Independent Pharmacies
- Neutral Sentiment: Zacks noted that MCK is a trending stock among users, reflecting elevated investor interest rather than a fundamental change in outlook. McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
- Neutral Sentiment: A separate portfolio update from TCW mentioned McKesson, but it does not appear to be a company-specific catalyst. TCW Concentrated Large Cap Growth Fund Q1 2026 Portfolio Activity
McKesson Stock Performance
McKesson (NYSE:MCK – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported $11.69 earnings per share for the quarter, beating analysts’ consensus estimates of $11.56 by $0.13. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. The business had revenue of $96.30 billion for the quarter, compared to analysts’ expectations of $101.35 billion. During the same period last year, the business earned $10.12 EPS. The company’s revenue was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. On average, equities analysts predict that McKesson Corporation will post 44.28 earnings per share for the current fiscal year.
McKesson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Monday, June 1st will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio is presently 8.53%.
Insider Activity
In other McKesson news, EVP Michele Lau sold 3,550 shares of McKesson stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total value of $2,701,869.50. Following the transaction, the executive vice president directly owned 3,247 shares of the company’s stock, valued at approximately $2,471,259.23. The trade was a 52.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Brian S. Tyler sold 8,463 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $775.13, for a total value of $6,559,925.19. Following the transaction, the chief executive officer directly owned 14,382 shares in the company, valued at approximately $11,147,919.66. The trade was a 37.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 20,285 shares of company stock valued at $15,546,137 in the last ninety days. 0.06% of the stock is currently owned by insiders.
Analysts Set New Price Targets
MCK has been the subject of several research reports. Raymond James Financial set a $970.00 target price on McKesson in a report on Thursday, March 5th. UBS Group raised their price target on McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Citigroup decreased their price objective on McKesson from $975.00 to $945.00 and set a “buy” rating for the company in a report on Thursday, May 14th. William Blair assumed coverage on shares of McKesson in a research note on Tuesday, April 28th. They issued an “outperform” rating for the company. Finally, Evercore reiterated an “outperform” rating on shares of McKesson in a report on Thursday, March 5th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $960.53.
Check Out Our Latest Analysis on McKesson
McKesson Company Profile
McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.
The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.
Read More
- Five stocks we like better than McKesson
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK – Free Report).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.
